Table 2.
Minimal inhibitory concentration and minimal bactericidal concentrations (MIC/MBC; µg/mL) of CSA-13 and CSA-13-IRDye800CW, against E. coli Xen14 and two clinical strains of uropathogenic E. coli (S1 and S2) isolated from patients with urinary tract infections in LB broth, urine and plasma.
| CSA-13 | CSA-13-IRDye 800CW | |||||
|---|---|---|---|---|---|---|
| E. coli Xen14 | E. coli S1* | E. coli S2* | E. coli Xen14 | E. coli S1* | E. coli S2* | |
| LB broth | 2/2 | 1/2 | 2/4 | 1/2 | 2/4 | 2/4 |
| Urine | 2/4 | 1/2 | 2/4 | 4/8 | 4/8 | 2/4 |
| Plasma | 4/8 | 2/4 | 4/8 | 4/8 | 4/8 | 4/8 |
*Clinical strain.